| Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration Between 2013 and 2016 |
19 |
| Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics |
17 |
| Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation |
16 |
| Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study |
16 |
| Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2017 |
15 |
| Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the Albumin-Mediated Hepatic Uptake Mechanism on the Basis of the Facilitated-Dissociation Model |
14 |
| A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes |
13 |
| The Roles of Xenobiotic Receptors: Beyond Chemical Disposition |
13 |
| Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites |
13 |
| The Phenomenon of Albumin-Mediated Hepatic Uptake of Organic Anion Transport Polypeptide Substrates: Prediction of the In Vivo Uptake Clearance from the In Vitro Uptake by Isolated Hepatocytes Using a Facilitated-Dissociation Model |
13 |
| A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the Metabolites in Safety Testing Regulatory Guidance |
12 |
| Substrate Selectivity Check of the Ergothioneine Transporter |
12 |
| A Clinical Quantitative Evaluation of Hepatobiliary Transport of [C-11] Dehydropravastatin in Humans Using Positron Emission Tomography |
11 |
| Cryopreserved Human Intestinal Mucosal Epithelium: A Novel In Vitro Experimental System for the Evaluation of Enteric Drug Metabolism, Cytochrome P450 Induction, and Enterotoxicity |
11 |
| Generation of Intestinal Organoids Suitable for Pharmacokinetic Studies from Human Induced Pluripotent Stem Cells |
11 |
| Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey |
11 |
| Direct Quantification of Cytochromes P450 and Drug Transporters-A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates |
10 |
| The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection |
10 |
| Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics |
10 |
| Predicting Human Clearance of Organic Anion Transporting Polypeptide Substrates Using Cynomolgus Monkey: In Vitro-In Vivo Scaling of Hepatic Uptake Clearance |
10 |
| Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds |
10 |
| Metabolism and Disposition of Volanesorsen, a 2 '-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species |
10 |
| Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities |
10 |
| Emerging Kidney Models to Investigate Metabolism, Transport, and Toxicity of Drugs and Xenobiotics |
10 |
| P450-Humanized and Human Liver Chimeric Mouse Models for Studying Xenobiotic Metabolism and Toxicity |
10 |
| A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects |
9 |
| Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells |
9 |
| Metabolism and Disposition of Siponimod, a Novel Selective S1P(1)/S1P(5) Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism |
9 |
| The Presence of a Transporter-Induced Protein Binding Shift: A New Explanation for Protein-Facilitated Uptake and Improvement for In Vitro-In Vivo Extrapolation |
9 |
| PBDEs Altered Gut Microbiome and Bile Acid Homeostasis in Male C57BL/6 Mice |
9 |
| A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters |
9 |
| Kidney Cortical Transporter Expression across Species Using Quantitative Proteomics |
8 |
| Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin |
8 |
| Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex |
8 |
| Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation |
8 |
| A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation |
8 |
| Mathematical and Experimental Validation of Flux Dialysis Method: An Improved Approach to Measure Unbound Fraction for Compounds with High Protein Binding and Other Challenging Properties |
8 |
| Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity |
8 |
| Pharmacokinetics, Metabolism, and Excretion of [C-14] Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans |
8 |
| Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease |
8 |
| Physiological Regulation of Drug Metabolism and Transport: Pregnancy, Microbiome, Inflammation, Infection, and Fasting |
8 |
| Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans |
8 |
| Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells |
8 |
| Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity |
8 |
| How to Determine the Role of the Microbiome in Drug Disposition |
8 |
| Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers |
7 |
| Application of Intestinal Epithelial Cells Differentiated from Human Induced Pluripotent Stem Cells for Studies of Prodrug Hydrolysis and Drug Absorption in the Small Intestines |
7 |
| The Molecular Mechanism Regulating Diurnal Rhythm of Flavin-Containing Monooxygenase 5 in Mouse Liver |
7 |
| Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach |
7 |
| Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate- Peroxisome Proliferator-Activated Receptor-gamma Activation |
7 |
